IL2RA and primary cutaneous T-cell non-Hodgkin lymphoma: A diphtheria toxin-based recombinant fusion toxin (Ontak) has been approved by the FDA for the treatment of human CD25+ cutaneous T-cell lymphoma (CTCL).